TP53 and adenocarcinoma: The Barrett-associated adenocarcinoma cell line JH-EsoAd1 in this model has a missense mutation in TP53 [29,30], which has been knocked out by CRISPR/Cas9 technology, resulting in three control parental lines retaining endogenous mut-p53 (referred to as “Parentals”) and three mut-p53 KO clones (referred to as “p53-KO”).